For Health Care Professionals Outside the US

Your Patients Get Convenience with
Once-daily Oral REVOLADE

REVOLADE is available in 4 dosage strengths,1 allowing for dosing flexibility and accommodating patient needs, including tapering off treatment2-5

REVOLADE dosing in ITP

See below for dietary guidelines during REVOLADE therapy
  • Titrate in 25-mg/day increments, up or down, to help patients reach their target platelet levels1
    • Adjust the dose no more frequently than once every 2 weeks
    • For patients with hepatic impairment, dose increases should occur no more frequently than once every 3 weeks
  • Do not exceed a dose of 75 mg/day1

Follow the detailed dosing and titration instructions in the Summary of Product Characteristics

REVOLADE dosing in severe aplastic anaemia (SAA)

See below for dietary guidelines during REVOLADE therapy

Titration in relapsed/refractory SAA1

  • Haematologic response requires dose titration, generally up to 150 mg
  • Titration to 150 mg may take up to 16 weeks after initiating REVOLADE
    • Adjust the dose in 50-mg increments every 2 weeks to achieve the target platelet count ≥50 x 109/L
    • For patients who initiate REVOLADE at 25 mg/day, the dose should be increased to 50 mg/day before increasing the dose in 50-mg increments
  • Do not exceed a dose of 150 mg/day

Follow the detailed dosing and titration instructions in the Summary of Product Characteristics

REVOLADE dosing in chronic hepatitis C virus–associated thrombocytopenia (HCVaT)

See below for dietary guidelines during REVOLADE therapy

  • Titrate in 25-mg/day increments, up or down1
    • Prior to initiating antiviral therapy, titrate as necessary to help patients reach the target platelet level necessary to initiate antiviral therapy
    • During antiviral therapy, titrate as necessary to avoid dose reductions of peginterferon due to decreasing platelet counts
  • Adjust the dose no more frequently than once every 2 weeks1
  • Platelet counts should be monitored every week before and after initiating antiviral therapy1
  • Do not exceed a dose of 100 mg/day1
  • Treatment with REVOLADE should be terminated when antiviral therapy is discontinued, unless otherwise justified1

Follow the detailed dosing and titration instructions in the Summary of Product Characteristics

Dietary guidelines

Considerations when taking REVOLADE

  • Patients can eat and drink normally throughout the day, taking REVOLADE at least 2 hours before or 4 hours after certain foods/products1
    • Dairy products or calcium-rich foods
    • Some mineral and vitamin supplements, including iron, calcium, magnesium, aluminium, selenium, and zinc
    • Antacids

References:

1. REVOLADE Summary of Product Characteristics. February 2019. 2. Bussel JB, Mahmud SN, Brigstocke SL, Torneten SM. Tapering eltrombopag in patients with chronic ITP: how successful is this and in whom does it work? Blood. 2015;126(23):1054. 3. González-López TJ, Pascual C, Álvarez-Román MT, et al. Successful discontinuation of eltrombopag after complete remission in patients with primary immune thrombocytopenia. Am J Hematol. 2015;90(3):E40-E43. 4. Taylor A, Westwood JP, Laskou F, McGuckin S, Scully M. Thrombopoietin receptor agonist therapy in thrombocytopenia: ITP and beyond. Br J Haematol. 2017;177(3):475-480. 5. Lucchini E, Palandri F, Volpetti S, et al. Eltrombopag as second line therapy in adult patients with primary immune thrombocytopenia (ITP) in attempt to achieve long-term remission. Preliminary analysis of a phase II, multicenter, prospective study by GIMEMA Group (the ESTIT Study). Presented at: 60th Annual American Society of Hematology Meeting and Exposition; December 1, 2018; San Diego, CA.